Cargando…

Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho

INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bygrave, Helen, Kranzer, Katharina, Hilderbrand, Katherine, Jouquet, Guillaume, Goemaere, Eric, Vlahakis, Nathalie, Triviño, Laura, Makakole, Lipontso, Ford, Nathan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047584/
https://www.ncbi.nlm.nih.gov/pubmed/21407815
http://dx.doi.org/10.1371/journal.pone.0017609
_version_ 1782199048635154432
author Bygrave, Helen
Kranzer, Katharina
Hilderbrand, Katherine
Jouquet, Guillaume
Goemaere, Eric
Vlahakis, Nathalie
Triviño, Laura
Makakole, Lipontso
Ford, Nathan
author_facet Bygrave, Helen
Kranzer, Katharina
Hilderbrand, Katherine
Jouquet, Guillaume
Goemaere, Eric
Vlahakis, Nathalie
Triviño, Laura
Makakole, Lipontso
Ford, Nathan
author_sort Bygrave, Helen
collection PubMed
description INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors determined by multivariate analysis. RESULTS: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl <50 ml/min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on TDF; renal function improved (CrCl≥50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl <50 ml/min were started in error, none developed severe renal impairment. CONCLUSION: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at lower CrCl thresholds are warranted.
format Text
id pubmed-3047584
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30475842011-03-15 Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho Bygrave, Helen Kranzer, Katharina Hilderbrand, Katherine Jouquet, Guillaume Goemaere, Eric Vlahakis, Nathalie Triviño, Laura Makakole, Lipontso Ford, Nathan PLoS One Research Article INTRODUCTION: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. METHODS: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors determined by multivariate analysis. RESULTS: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl <50 ml/min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on TDF; renal function improved (CrCl≥50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl <50 ml/min were started in error, none developed severe renal impairment. CONCLUSION: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at lower CrCl thresholds are warranted. Public Library of Science 2011-03-02 /pmc/articles/PMC3047584/ /pubmed/21407815 http://dx.doi.org/10.1371/journal.pone.0017609 Text en Bygrave et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bygrave, Helen
Kranzer, Katharina
Hilderbrand, Katherine
Jouquet, Guillaume
Goemaere, Eric
Vlahakis, Nathalie
Triviño, Laura
Makakole, Lipontso
Ford, Nathan
Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title_full Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title_fullStr Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title_full_unstemmed Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title_short Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
title_sort renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural lesotho
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047584/
https://www.ncbi.nlm.nih.gov/pubmed/21407815
http://dx.doi.org/10.1371/journal.pone.0017609
work_keys_str_mv AT bygravehelen renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT kranzerkatharina renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT hilderbrandkatherine renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT jouquetguillaume renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT goemaereeric renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT vlahakisnathalie renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT trivinolaura renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT makakolelipontso renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho
AT fordnathan renalsafetyofatenofovircontainingfirstlineregimenexperiencefromanantiretroviralcohortinrurallesotho